Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs)

Journal of Cell Science

Volumn 115, Issue 17, 2002, Pages 3427-3438

  Lafleur, Marc A ^a   Handsley, Madeleine M ^a   Knäuper, Vera ^a   Murphy, Gillian ^a   Edwards, Dylan R ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Angiogenesis; Endothelial; Fibrin gels; MT Ps; Tubulogenesis

Indexed keywords

ANGIOGENIC FACTOR; APROTININ; ENZYME ANTIBODY; FIBRIN; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; HEMOPEXIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; MUTANT PROTEIN; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; PEPSTATIN; SCATTER FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4; VASCULOTROPIN;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL CULTURE; CELL TYPE; COCULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; EPITHELIUM CELL; GEL; GLIOMA CELL; HUMAN; HUMAN CELL; MICROVASCULATURE; PRIORITY JOURNAL; TUMOR CELL;

EID: 0036712828     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3
2. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
3. Requirement of vascular integrin alpha v beta 3 for angiogenesis
4. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity
5. Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases
6. The specificity of TIMP-2 for matrix metalloproteinases can be modified by single amino acid mutations
7. Mechanisms of angiogenesis and arteriogenesis
8. Membrane-type matrix metalloproteinases in human dermal microvascular endothelial cells: Expression and morphogenetic correlation
9. Angiogenesis: Models and modulators
10. Matrix metalloproteinases generate angiostatin: Effects on neovascularization
11. Matrix metalloproteinases and the development of cancer
12. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinaes
13. MT1-MMP on the cell surface causes focal degradation of gelatin films
14. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation
15. Characterisation of the role of the 'MT-Loop'; an eight amino acid insertion specific to progelatinase A (MMP2) activating membrane-type matrix metalloproteinases
16. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells
17. Angiogenesis
18. Blood vessel formation: What is its molecular basis?
19. Membrane type 1-matrix metalloproteinases is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling
20. Expression of matrix metalloproteinase-2-cleaved laminin-5 breast remodeling stimulated by sex steroids
21. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin
22. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins
23. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3
24. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis
25. Culture of human endothelial cells derived from umbilical veins
26. Membrane type 1-matrix metalloproteinase is involved in the formation of hepatocyte growth factor/scatter factor-induced branching tubules in Madin-Darby canine kidney epithelial cells
27. Perivascular cells regulate endothelial membrane type-1 matrix metalloproteinase activity
28. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3)
29. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase A overexpressed in brain tumors
30. Identification of soluble type of MT-MMP-3 formed by alternatively spliced mRNA
31. Lumen formation during angiogenesis in vitro involves phagocytic activity, formation and secretion of vacuoles, cell death, and capillary tube remodelling by different populations of endothelial cells
32. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
33. Relating matrix metalloproteinase structure to function: Why the "hemopexin" domain?
34. Cellular mechanisms for focal proteolysis and the regulation of the microenvironment
35. Pathogenesis of tumor stroma generation: A critical role for leaky blood vessels and fibrin deposition
36. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloproteinase docking to invadopodia is required for cell invasion
37. Matrix metalloproteinases: Biologic activity and clinical implications
38. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
39. First steps of tumor-related angiogenesis
40. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9)
41. Extracellular proteolysis and angiogenesis
42. Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro
43. Angiogenesis: A paradigm for balanced extracellular proteolysis during cell migration and morphogenesis
44. Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2
45. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo
46. Hyaluronan oligosaccharides induce tube formation of a brain endothelial cell line in vitro
47. Mechanisms of angiogenesis
48. The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells
49. Characterization of a truncated recombinant form of human membrane type 3 matrix metalloproteinase
50. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
51. Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme
52. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients
53. In vitro angiogenesis is modulated by the mechanical properties of fibrin gels and is related to αvβ3 integrin localization
54. Role of fibrin and plasminogen activators in repair-associated angiogenesis: In vitro studies with human endothelial cells
55. A novel, quantitative model for study of endothelial cell migration and sprout formation within three-dimensional collagen matrices
56. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation
57. The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: A kinetic analysis of the inhibition of gelatinase A
58. Tyrosine 36 plays a critical role in the interaction of the AB loop of tissue inhibitor of metalloproteinases-2 with matrix metalloproteinase-14
59. Proteolysis of insulin-like growth factor binding protein-3 in serum from pregnant, non-pregnant and fetal rats by matrix metalloproteinases and serine proteases
60. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo
61. Functional roles for PECAM- I (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels
62. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I